CTOs on the Move

B-Bridge International

www.b-bridge.com

 
B-Bridge International is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.b-bridge.com
  • 20813 Stevens Creek Blvd Ste 200
    Cupertino, CA USA 95014
  • Phone: 408.252.6200

Executives

Name Title Contact Details

Similar Companies

Novartis Animal Health, US

Novartis Animal Health, US is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Horizon Discovery

Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted...

Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.

AnGes Inc

AnGes Inc is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eleven Therapeutics

Eleven Therapeutics is at the forefront of mRNA therapeutics innovation, harnessing combinatorial chemistry, synthetic biology, and artificial intelligence to develop next-generation therapies. The company`s pipeline includes extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. Proprietary high-throughput screening platforms, TERA™ and DELiveri™, underpin Eleven Therapeutics` pipeline by generating chemically modified xRNAs and cell-penetrating delivery carriers. Founded in 2020 by world-leading scientists across Cambridge (UK), Boston (US), and Tel Aviv (Israel), Eleven Therapeutics is supported by top-tier venture capitalists and the Bill & Melinda Gates Foundation.